Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • ovarian cancer

    - PMLiVE

    Corcept Therapeutics reports positive phase 3 results in ovarian cancer treatment

    The company also plans to expand its phase 2 BELLA study to include three new study arms

    - PMLiVE

    AbbVie’s Elahere granted MHRA approval to treat platinum-resistant ovarian cancer

    Approximately 7,500 people are diagnosed with ovarian cancer every year in the UK

    - PMLiVE

    Merck shares promising phase 3 results for Keytruda in ovarian cancer

    Approximately 20,890 cases of the disease are expected to be diagnosed in the US this year

    - PMLiVE

    FDA approves Verastem Oncology’s combination therapy for rare ovarian cancer type

    Approximately 6,000 to 8,000 women in the US are living with low-grade serous ovarian cancer

    - PMLiVE

    AbbVie’s Elahere shows consistent survival benefits in late-stage ovarian cancer trial

    Approximately 20,000 cases of the disease are diagnosed in the US every year

    - PMLiVE

    NICE recommends pharmaand’s Rubraca for advanced ovarian cancer

    An estimated 7,500 new cases of the disease were diagnosed in the UK between 2017 and 2019

    - PMLiVE

    Merck shares positive phase 3 results for Keytruda/Lynparza regimen in ovarian cancer

    Ovarian cancer is the seventh most common cancer in women globally

    - PMLiVE

    Bringing Clinicians Together for Oncology Education at ESMO 2024

    ESMO 2024 comes with the debut of 2 new, exciting symposia hosted by the MedscapeLIVE! team. The symposia build on nearly 30 years of Medscape’s experience and excellence in both...

    Medscape Education

    - PMLiVE

    Genmab to expand oncology portfolio through $1.8bn ProfoundBio acquisition

    The deal includes a next-generation ADC being evaluated as a treatment for ovarian cancer and other solid tumours

    - PMLiVE

    AbbVie’s Elahere granted full FDA approval for previously-treated ovarian cancer

    The company recently gained access to the therapy through its $10.1bn acquisition of ImmunoGen

    - PMLiVE

    AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer

    Approximately 7,400 new cases of the disease are diagnosed in the UK every year

    - PMLiVE

    AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition

    The agreement grants the company access to FDA-approved ovarian cancer drug Elahere

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links